

# Global Benign Prostatic Hyperplasia Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

<https://marketpublishers.com/r/G30058F5625GEN.html>

Date: August 2018

Pages: 117

Price: US\$ 3,480.00 (Single User License)

ID: G30058F5625GEN

## Abstracts

Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease

### SCOPE OF THE REPORT:

This report studies the Benign Prostatic Hyperplasia Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostatic Hyperplasia Therapeutics market by product type and applications/end industries.

The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market.

The global Benign Prostatic Hyperplasia Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostatic Hyperplasia Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Abbott Laboratories

Allergan plc

Astellas Pharma

Boehringer Ingelheim Pharma GmbH & Co. KG

Eli Lilly and Company

GlaxoSmithKline plc

Merck & Co.

Pfizer

Sanofi

Teva Pharmaceutical Industries Limited

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Alpha blocker

5-Alpha reductase inhibitor

Phosphodiesterase-5 inhibitor

Others

Market Segment by Applications, can be divided into

Mono drug therapy

Combination drug therapy

## Contents

### 1 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET OVERVIEW

- 1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics
- 1.2 Classification of Benign Prostatic Hyperplasia Therapeutics by Types
  - 1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Comparison by Types (2017-2023)
  - 1.2.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Types in 2017
  - 1.2.3 Alpha blocker
  - 1.2.4 5-Alpha reductase inhibitor
  - 1.2.5 Phosphodiesterase-5 inhibitor
  - 1.2.6 Others
- 1.3 Global Benign Prostatic Hyperplasia Therapeutics Market by Application
  - 1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
  - 1.3.2 Mono drug therapy
  - 1.3.3 Combination drug therapy
- 1.4 Global Benign Prostatic Hyperplasia Therapeutics Market by Regions
  - 1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
    - 1.4.1 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
    - 1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
    - 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
    - 1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
    - 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
- 1.5 Global Market Size of Benign Prostatic Hyperplasia Therapeutics (2013-2023)

### 2 MANUFACTURERS PROFILES

- 2.1 Abbott Laboratories
  - 2.1.1 Business Overview
  - 2.1.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications

- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
- 2.2 Allergan plc
  - 2.2.1 Business Overview
  - 2.2.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
    - 2.2.2.1 Product A
    - 2.2.2.2 Product B
  - 2.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
- 2.3 Astellas Pharma
  - 2.3.1 Business Overview
  - 2.3.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
    - 2.3.2.1 Product A
    - 2.3.2.2 Product B
  - 2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
- 2.4 Boehringer Ingelheim Pharma GmbH & Co. KG
  - 2.4.1 Business Overview
  - 2.4.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
    - 2.4.2.1 Product A
    - 2.4.2.2 Product B
  - 2.4.3 Boehringer Ingelheim Pharma GmbH & Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
- 2.5 Eli Lilly and Company
  - 2.5.1 Business Overview
  - 2.5.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
    - 2.5.2.1 Product A
    - 2.5.2.2 Product B
  - 2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
- 2.6 GlaxoSmithKline plc
  - 2.6.1 Business Overview
  - 2.6.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
    - 2.6.2.1 Product A
    - 2.6.2.2 Product B
  - 2.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

## 2.7 Merck & Co.

### 2.7.1 Business Overview

### 2.7.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications

#### 2.7.2.1 Product A

#### 2.7.2.2 Product B

### 2.7.3 Merck & Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

## 2.8 Pfizer

### 2.8.1 Business Overview

### 2.8.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications

#### 2.8.2.1 Product A

#### 2.8.2.2 Product B

### 2.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

## 2.9 Sanofi

### 2.9.1 Business Overview

### 2.9.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications

#### 2.9.2.1 Product A

#### 2.9.2.2 Product B

### 2.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

## 2.10 Teva Pharmaceutical Industries Limited

### 2.10.1 Business Overview

### 2.10.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications

#### 2.10.2.1 Product A

#### 2.10.2.2 Product B

### 2.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

## **3 GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET COMPETITION, BY PLAYERS**

### 3.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Share by Players (2013-2018)

### 3.2 Market Concentration Rate

#### 3.2.1 Top 5 Benign Prostatic Hyperplasia Therapeutics Players Market Share

#### 3.2.2 Top 10 Benign Prostatic Hyperplasia Therapeutics Players Market Share

### 3.3 Market Competition Trend

## **4 GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE BY REGIONS**

4.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Regions

4.2 North America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

## **5 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS REVENUE BY COUNTRIES**

5.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

5.2 USA Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

## **6 EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS REVENUE BY COUNTRIES**

6.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

## **7 ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS REVENUE BY COUNTRIES**

7.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

7.2 China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

## **8 SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS REVENUE BY COUNTRIES**

8.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

## **9 MIDDLE EAST AND AFRICA REVENUE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS BY COUNTRIES**

9.1 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate



(2013-2018)

9.3 UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate  
(2013-2018)

9.4 Egypt Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate  
(2013-2018)

9.5 Nigeria Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate  
(2013-2018)

9.6 South Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate  
(2013-2018)

## **10 GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENT BY TYPE**

10.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by  
Type (2013-2018)

10.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type  
(2018-2023)

10.3 Alpha blocker Revenue Growth Rate (2013-2023)

10.4 5-Alpha reductase inhibitor Revenue Growth Rate (2013-2023)

10.5 Phosphodiesterase-5 inhibitor Revenue Growth Rate (2013-2023)

10.6 Others Revenue Growth Rate (2013-2023)

## **11 GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENT BY APPLICATION**

11.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by  
Application (2013-2018)

11.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application  
(2018-2023)

11.3 Mono drug therapy Revenue Growth (2013-2018)

11.4 Combination drug therapy Revenue Growth (2013-2018)

## **12 GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE FORECAST (2018-2023)**

12.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast  
(2018-2023)

12.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Regions  
(2018-2023)

12.3 North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Data Source

## List Of Tables

### LIST OF TABLES AND FIGURES

Figure Benign Prostatic Hyperplasia Therapeutics Picture

Table Product Specifications of Benign Prostatic Hyperplasia Therapeutics

Table Global Benign Prostatic Hyperplasia Therapeutics and Revenue (Million USD)

Market Split by Product Type

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Types in 2017

Figure Alpha blocker Picture

Figure 5-Alpha reductase inhibitor Picture

Figure Phosphodiesterase-5 inhibitor Picture

Figure Others Picture

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Application (2013-2023)

Figure Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Applications in 2017

Figure Mono drug therapy Picture

Figure Combination drug therapy Picture

Table Global Market Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Comparison by Regions 2013-2023

Figure North America Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Europe Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure South America Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Table Abbott Laboratories Basic Information, Manufacturing Base and Competitors

Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Type and Applications

Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Allergan plc Basic Information, Manufacturing Base and Competitors
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Boehringer Ingelheim Pharma GmbH & Co. KG Basic Information, Manufacturing Base and Competitors
Table Boehringer Ingelheim Pharma GmbH & Co. KG Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Boehringer Ingelheim Pharma GmbH & Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Merck & Co. Basic Information, Manufacturing Base and Competitors
Table Merck & Co. Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Merck & Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Type and Applications
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
Table Teva Pharmaceutical Industries Limited Basic Information, Manufacturing Base and Competitors

Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia  
Therapeutics Type and Applications

Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia  
Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by  
Players (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players  
(2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players in  
2016

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players in  
2017

Figure Global Top 5 Players Benign Prostatic Hyperplasia Therapeutics Revenue  
Market Share in 2017

Figure Global Top 10 Players Benign Prostatic Hyperplasia Therapeutics Revenue  
Market Share in 2017

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and  
Growth Rate (%) (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by  
Regions (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by  
Regions (2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by  
Regions (2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by  
Regions in 2017

Figure North America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth  
Rate (2013-2018)

Figure Europe Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate  
(2013-2018)

Figure Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue and Growth  
Rate (2013-2018)

Figure South America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth  
Rate (2013-2018)

Figure Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue and  
Growth Rate (2013-2018)

Table North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries  
(2013-2018)

Table North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share

by Countries (2013-2018)

Figure North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2017

Figure USA Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Table Europe Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2013-2018)

Figure Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2017

Figure Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure UK Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Table Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2013-2018)

Figure Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2017

Figure China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)



Figure India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Table South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)

Table South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2017

Figure Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Colombia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Table Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2013-2018)

Table Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2017

Figure Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Egypt Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure Nigeria Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Figure South Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Type (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type

(2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type

(2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type in 2017

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Type (2018-2023)

Figure Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Type (2018-2023)

Figure Global Alpha blocker Revenue Growth Rate (2013-2018)

Figure Global 5-Alpha reductase inhibitor Revenue Growth Rate (2013-2018)

Figure Global Phosphodiesterase-5 inhibitor Revenue Growth Rate (2013-2018)

Figure Global Others Revenue Growth Rate (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application in 2017

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Application (2018-2023)

Figure Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Application (2018-2023)

Figure Global Mono drug therapy Revenue Growth Rate (2013-2018)

Figure Global Combination drug therapy Revenue Growth Rate (2013-2018)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate Forecast (2018 -2023)

Table Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Forecast by Regions (2018-2023)

Figure Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share Forecast by Regions (2018-2023)

Figure North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

Figure Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

Figure Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)



Figure South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

Figure Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)

## I would like to order

Product name: Global Benign Prostatic Hyperplasia Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Product link: <https://marketpublishers.com/r/G30058F5625GEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G30058F5625GEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

